Abstract:Results of clinical trials with the old and newer anticoagulants support the recommendation that lower doses (resulting in lower anticoagulant exposure) should be used to prevent venous thrombosis rather than to treat established venous thrombosis or to prevent embolic stroke in atrial fibrillation (AF). In this brief commentary, we will review the evidence for using different dosing regimens for each of the three indications ([Table 1]) and offer potential explanations for these dosing differences. Anticoagulants VTE prevention Acute VTE treatment Stroke prevention in AF Unfractionated heparin 5,000 IU subcutaneously q8h or q12h IV bolus 5,000 IU (or 80 IU/kg) followed by 20 IU/Kg/h adjusted according to aPTT – Dalteparin 5,000 IU once daily 100 IU/kg twice daily or 200 IU/kg once daily – Enoxaparin 30 mg twice daily or 40 mg daily 1 mg/kg twice daily or 1.5 mg/kg once daily – Tinzaparin 50–75 IU/kg 175 IU/kg once daily – Fondaparinux 2.5 mg once daily 5 mg once daily for weight 100 kg Dabigatran[a] 110 mg within 1–4 h after surgery then 150 mg or 220 mg daily 150 mg twice daily after 5–10 d of parenteral anticoagulant 150 mg twice daily Apixaban[b] Apixaban 2.5 mg twice daily 10 mg twice daily for 7 d then 5 mg twice daily 5 mg twice daily Rivaroxaban[c] Rivaroxaban 10 mg once daily 15 mg twice daily for 21 d then 20 mg once daily 20 mg once daily Edoxaban[d] – 60 mg once daily after 5–10 d of parenteral anticoagulant 60 mg once daily Abbreviations: AF, atrial fibrillation; aPTT, activated partial thromboplastin time; IU, international units; IV, intravenous; VTE, venous thromboembolism. a Dabigatran: For patients ≥80 years or with high bleeding risk—110 mg twice daily. b Apixaban: For AF—2.5 mg twice daily for patients at least 2 of the following: ≥80 years, ≤60 kg, or with creatinine ≥1.5 mg/dL. c Rivaroxaban: For AF—15 mg daily with creatinine clearance 15–50 mL/min. d Edoxaban: 30 mg daily for one of the following: creatinine clearance 15–50 mL/min, ≤60 kg body weight, or concurrent use of potent P-glycoprotein inhibitors. Before the 1970s, the use of anticoagulants to prevent and treat thrombosis was inconsistent and the dose used was left to the whim of the treating physician.[1] The situation changed in the early 1970s when VJ Kakkar showed that low doses of unfractionated heparin (UFH) given by subcutaneous injection (5,000 units twice or three times daily) were effective in preventing venous thromboembolism (VTE),[2] [3] and when Basu et al reported that the risk of recurrent VTE in patients treated with continuous intravenous UFH was increased when the anticoagulation intensity, as measured by the activated partial thromboplastin time (aPTT), fell below 1.5 times the control value.[4] Both reports changed clinical practice, although the study by Basu et al was not well designed by current standards. Since then, several well-designed clinical trials with a variety of anticoagulants have confirmed the observation that higher doses of anticoagulants are required to treat than to prevent VTE. The need for higher doses of UFH to treat than to prevent VTE was first demonstrated in 1980 when low-dose UFH, which was highly effective in preventing VTE, was shown to be ineffective at preventing the extension of acute deep vein thrombosis.[5] [6] Likewise, based on the results of phase III studies, the recommended and approved doses of low molecular weight heparins, fondaparinux, dabigatran, apixaban, and rivaroxaban were also found to be lower for the prevention than the treatment of VTE ([Table 1]). Warfarin was an exception since it was used with an identical intensity for the prevention and treatment of VTE. However, when used for the prevention of postoperative VTE, its full anticoagulant effect was not manifest for 4 to 6 days after surgery.[7] Therefore, its anticoagulant effect was of low intensity in the early postoperative period. The adequacy of a lower international normalized ratio (INR) level was supported by the study by Levine et al which showed that warfarin at a targeted INR of 1.3 to 1.9 was effective in preventing VTE in patients with breast cancer who were receiving chemotherapy.[8] Anticoagulants were generally not recommended for stroke prevention in patients with nonvalvular AF until the results of clinical trials comparing warfarin with no treatment were published in the early 1990s.[9] These randomized trials showed that warfarin at an intensity equivalent to an INR of 2.0 to 3.0 was highly effective in reducing the risk of stroke in nonvalvular AF. Importantly, results of a subgroup analysis of one trial and of case-control studies suggested that the efficacy of warfarin was reduced when the INR fell below 2.[10] In one of these -Abstract Truncated-

Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic …

Selection of Warfarin or One of the New Oral Antithrombotic Agents for Long-Term Prevention of Stroke among Persons with Atrial Fibrillation

Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis

Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation

Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Comprehensive Review

Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature

Oral anticoagulation: preparing for change

Direct Acting Oral Anticoagulant vs. Warfarin in the Prevention of Thromboembolism in Patients With Non-valvular Atrial Fibrillation With Valvular Heart Disease—A Systematic Review and Meta-Analysis

When Direct Oral Anticoagulants Should Not Be Standard Treatment

Oral anticoagulant treatment in patients with atrial fibrillation early after valvular intervention: a nationwide cohort study

Trends in anticoagulant prescribing: a review of local policies in English primary care

Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline

New developments in anticoagulants: past, present and future

The European Heart Rhythm Association Practical Guide on the Use of New Oral Anticoagulants in Patients with Non-valvular Atrial Fibrillation - A Brief Summary

Comparison of the new oral anticoagulant drug with warfarin to prevent stroke in patients with atrial fibrillation

Aetiology, secondary prevention strategies and outcomes of ischaemic stroke despite oral anticoagulant therapy in patients with atrial fibrillation

Emerging therapies for stroke prevention in atrial fibrillation

Fitting the right non-vitamin K antagonist oral anticoagulant to the right patient with non-valvular atrial fibrillation: an evidence-based choice

Comparative effectiveness and safety of oral anticoagulants for atrial fibrillation in real-world practice: a population-based cohort study protocol

Dosing Intensity of Anticoagulants for the Prevention and Treatment of Venous Thromboembolism and the Prevention of Stroke in Atrial Fibrillation: Why is There a Difference?

Direct Oral Anticoagulants for Stroke Prevention in Patients with Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials